Methotrexate-treated ectopic pregnancy: beta human chorionic gonadotropin serum changes as a success predictor using...

Area of Science:

• Gynecology
• Reproductive Medicine
• Pharmacology

Background:

• Ectopic pregnancy treatment with methotrexate may require surgical rescue due to tubal rupture or treatment failure.
• Elevated beta human chorionic gonadotropin (β-hCG) levels are a key indicator of treatment failure.
• Predicting medical treatment outcomes can help avoid unnecessary surgical interventions.

Purpose of the Study:

• To determine if relative changes in serum β-hCG can predict the success of methotrexate therapy for ectopic pregnancy.
• To identify a threshold for β-hCG changes that indicates successful medical management.
• To facilitate clinical decisions regarding surgical rescue versus expectant management.

Main Methods:

• A retrospective observational study involving 115 patients with ectopic pregnancy treated with methotrexate (50mg/m²).
• Analysis of relative β-hCG concentration changes between day 1 and day 4 post-injection.
• Application of standard statistical tests to evaluate β-hCG dynamics.

Main Results:

• Methotrexate treatment achieves 95% success if the relative β-hCG change from day 1 to day 4 is between -1.02 and 0.15.
• A relative β-hCG change between 0.54 and 1.2 indicates treatment failure with 95% probability.
• A cut-off value of 0.15 for relative β-hCG change can predict a positive treatment outcome.

Conclusions:

• Negative relative β-hCG changes by day 4 of methotrexate therapy predict successful treatment.
• A cut-off point of 0.15 for relative β-hCG change is proposed for predicting treatment success.
• Expectant management is recommended for cases with successful β-hCG response, absent surgical indications.